(Q31148439)

29 June 2017

1 reference

title

Rationale for early intervention with immunomodulatory treatments (English)

1 reference

29 June 2017

Mar Tintoré

1

0 references

publication date

1 March 2008

1 reference

29 June 2017

1 reference

29 June 2017

volume

255 Suppl 1

1 reference

29 June 2017

page(s)

37-43

1 reference

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

29 June 2017

cites work

1 reference

12 December 2020

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

12 December 2020

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

1 reference

12 December 2020

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

1 reference

12 December 2020

ECTRIMS 2006. Abstracts of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. September 27-10, 2006. Madrid, Spain

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

1 reference

12 December 2020

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

12 December 2020

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

10.1007/S00415-008-1006-4

Identifiers

DOI

1 reference

Dimensions Publication ID

29 June 2017

1014750862

0 references

1 reference